MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Arbutus Biopharma Corp

Fermé

4.18 -3.02

Résumé

Variation du prix de l'action

24h

Actuel

Min

4.16

Max

4.28

Chiffres clés

By Trading Economics

Revenu

27M

2.5M

Ventes

9M

11M

Marge bénéficiaire

23.494

Employés

44

EBITDA

27M

2.6M

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

192M

832M

Ouverture précédente

7.2

Clôture précédente

4.18

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Arbutus Biopharma Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 oct. 2025, 20:45 UTC

Résultats

Costco Wholesale Sales Climb in September, Early October

8 oct. 2025, 20:12 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

TaskUs Shares Fall After Holders Reject Take-Private Deal

8 oct. 2025, 16:39 UTC

Principaux Mouvements du Marché

Mining Shares Rise as Gold Prices Soar

8 oct. 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8 oct. 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8 oct. 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Finance Acquisition Using Internal Funds

8 oct. 2025, 23:17 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8 oct. 2025, 23:16 UTC

Acquisitions, Fusions, Rachats

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8 oct. 2025, 21:54 UTC

Market Talk
Résultats

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8 oct. 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8 oct. 2025, 21:26 UTC

Market Talk
Résultats

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8 oct. 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8 oct. 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs Will Remain a Publicly Traded Co >TASK

8 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8 oct. 2025, 18:45 UTC

Acquisitions, Fusions, Rachats

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8 oct. 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8 oct. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

8 oct. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8 oct. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 oct. 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8 oct. 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8 oct. 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8 oct. 2025, 15:44 UTC

Acquisitions, Fusions, Rachats

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8 oct. 2025, 15:44 UTC

Acquisitions, Fusions, Rachats

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8 oct. 2025, 15:43 UTC

Acquisitions, Fusions, Rachats

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8 oct. 2025, 15:42 UTC

Acquisitions, Fusions, Rachats

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Comparaison

Variation de prix

Arbutus Biopharma Corp prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

3.255 / 3.365Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Weak Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
help-icon Live chat